The backbone of breakthroughs: Insights into clinical trial supply management
Behind every successfully approved treatment lies a nexus of clinical …
Newsletters and Deep Dive digital magazine
Behind every successfully approved treatment lies a nexus of clinical …
US intelligence services advised the authors of the BIOSECURE Act …
Bristol-Myers Squibb’s hopes of adding a new indication to the label …
On Tuesday 19th March, pharmaphorum headed to King’s Place, London …
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment …
Scientists have developed a new test for a biomarker in brain tissue …
An intriguing new study has suggested that there could be a …
Agile, responsive regulation helps early breast cancer patients to …
Beckley Psytech, just months away from a readout of a phase 2b trial …
Moderna’s efforts to develop a range of mRNA vaccines for influenza …
Sometimes the conversation about drug pricing within the pharma …
As the cell and gene therapy industry grapples with infrastructure …
US intelligence services advised the authors of the BIOSECURE Act that that WuXi AppTec shared confidential data on US customers with the Chinese government, according to
Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.
Over the last five years, a confluence of trends have combined to reshape the reality of clinical research. COVID-19 pushed decentralised trials into the mainstream.
It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.
We are living in an era of unprecedented advances in cancer treatments with transformative therapies being regularly approved.
The PM Society Digital Awards 2024 have opened for entries!
Exciting developments in the world of peptides!